SlideShare uma empresa Scribd logo
1 de 53
Clostridium difficile Infection (CDI) What is it? Modes of transmission? Environmental Sources? Control Measures?
Clostridium difficile ,[object Object],[object Object]
Clostridium difficile ,[object Object],[object Object],[object Object]
Overview: Clostridium difficile ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Pseudo-membranous colitis Healthy colon
New Strain of C.difficile ,[object Object],[object Object]
States with BI/NAP1/027 strain of  C. difficile   (N=40), October, 2008 DC PR AK HI
Lethal hospital bug cases rocket, United Kingdom ,[object Object],[object Object],[object Object],BBC News. http://news.bbc.co.uk/2/hi/health/4186834.stm
C.difficile – On the Rise ,[object Object],[object Object],[object Object]
What are the risk factors  for CDI ? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Antibiotics and  C. difficile? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Proton Pump Inhibitors ,[object Object],[object Object],[object Object],[object Object],[object Object]
Stomach Acid-Suppressing Medications and Community-Acquired CDAD, England From Dial S, et al.  JAMA.   2005;294:2989-2995 .
Severe CDAD in Populations Previously at  Low Risk—Four States, 2005  CDC.  MMWR.  2005;54:1201-1205 . 13 (39) 5 (50) 8 (35) Relapse 5 (15) 2 (20) 3 (13) ER visit necessary 10 (24) 4 (40) 6 (26) Hospitalization necessary 8 (24) 2 (20) 6 (26) Bloody diarrhea 24 (73) 9 (90) 15 (65) Antimicrobial exposure 25 (76) 10 (100) 15 (65) Female 11 (33) 0 (0) 11 (48) Aged < 18 years Total  (N=33) Peripartum (N=10) Community (N=23) Characteristic,  No. (%)
Other Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Some retail meats    contain  C. difficile   ,[object Object],[object Object],[object Object],[object Object]
CDC - Epidemiology   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
New Surveillance Definitions
NEBH Cases Per New Definitions
Control Measures in August 08 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Zimek Decontamination Unit ,[object Object],[object Object],[object Object],[object Object]
20 4 3 3 10 Total 0 0 0 0 0 Sep 0 0 0 0 0 Aug  1 0 0 0 1 July 2 0 0 1 1 June 2 1 0 0 1 May 3 2 0 0 1 April 2 0 1 1 0 March 2 0 0 0 2 February 1 0 0 0 1 January 5 1 1 1 2 December 0 0 0 0   November 2 0 1 0 1 October Total Community-acquired Indeterminate Community Onset – HAI Hosp Onset Month
0.0 0.11 Rate/PtDays 0.28 Rate/PtDays 0 3 Comm Onset HA 8 Comm Onset HA         0.14 0.35 Rate/PtDays 0.45 Rate/PtDays 1 10 Hospital Onset 13 Hospital Onset         0.14 0.46 Rate/PtDays 0.73 Rate/PtDays 6911 28382 Patient Days 28914 Patient Days 1 13 Total HAI 21 Total HAI FY10 1 st  Qtr FY09 FY08
Outbreak Situations
A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a  teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005 Mar;26(3):273-80. ,[object Object],[object Object],[object Object],[object Object],[object Object]
A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching  hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005 Mar;26(3):273-80. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Bacteria That Strikes Elderly Spreads in  Canadian Hospitals   August 9, 2004   ,[object Object],[object Object],[object Object],[object Object]
Clinical Manifestation   ,[object Object],[object Object],[object Object]
Antidiarrheal Agents ,[object Object]
Non-Specific Colitis ,[object Object],[object Object],[object Object],[object Object]
Fulminant Colitis ,[object Object],[object Object]
How can  C. difficile  spores   be spread?
How can  C. difficile -associated disease be spread?   ,[object Object],[object Object],[object Object],[object Object]
Hands and Gloved Hands as Sources for Spread ,[object Object],[object Object],[object Object],[object Object],Clinical Infectious Diseases, February 2008.
Clostridium difficile contamination of blood pressure  cuffs: a call for a closer look at gloving practices in  the era of universal precautions.  Manian FA, et al.   Infect Control Hosp Epidemiol. 1996 Mar;17(3):180-2. ,[object Object],[object Object]
[object Object],[object Object],[object Object],Transmission Factors
Transmission ,[object Object],[object Object],[object Object],[object Object]
Reservoirs for Spores ,[object Object]
Clinical and molecular epidemiology of sporadic  and clustered cases of nosocomial Clostridium difficile diarrhea Samore MH, et al. Division of Infectious Diseases, New England Deaconess Hospital Am J Med. 1996 Jan;100(1):32-40. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Environmental Sources ,[object Object],[object Object],[object Object],[object Object],[object Object]
How is  C. difficile -associated  disease diagnosed?   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Hand Hygiene Key Prevention Measure to Prevent Spread ,[object Object],[object Object],[object Object]
ALCOHOL-BASED HAND RUB Not Effective Against C.difficile   ,[object Object],[object Object],[object Object]
SPECIAL CONTACT PRECAUTIONS ,[object Object],[object Object],[object Object],[object Object],[object Object]
Special Contact Precautions ,[object Object],[object Object],[object Object]
Protocol to Discontinue  Contact  Precautions   ,[object Object],[object Object]
Environmental Disinfection   ,[object Object],[object Object],[object Object],[object Object],[object Object]
Consider “GloGerm” Studies ,[object Object],[object Object]
Environmental Cleaning Study ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Therapy for C. difficile ,[object Object],[object Object],[object Object],[object Object]
Therapy  continued….. ,[object Object],[object Object],[object Object],[object Object]
Relapse of C. Difficile ,[object Object]
Relapse ,[object Object],[object Object],[object Object]
In Summary….. ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Mais conteúdo relacionado

Mais procurados

The new β lactamases
The new β lactamasesThe new β lactamases
The new β lactamases
Neha Sharma
 

Mais procurados (20)

Clostridium difficile
Clostridium difficileClostridium difficile
Clostridium difficile
 
clostridium difficile by Ismail surchi
clostridium difficile by Ismail surchi clostridium difficile by Ismail surchi
clostridium difficile by Ismail surchi
 
Clostridium difficile powerpoint presentation
Clostridium difficile powerpoint presentationClostridium difficile powerpoint presentation
Clostridium difficile powerpoint presentation
 
Rotavirus
RotavirusRotavirus
Rotavirus
 
Antibiotic resistance
Antibiotic resistanceAntibiotic resistance
Antibiotic resistance
 
LSBU C Diff 2016
LSBU C Diff 2016LSBU C Diff 2016
LSBU C Diff 2016
 
Ampc c beta lactamases
Ampc c beta lactamases Ampc c beta lactamases
Ampc c beta lactamases
 
Rotavirus
RotavirusRotavirus
Rotavirus
 
Clostridium difficile by Dr.T.V.Rao MD
Clostridium difficile by Dr.T.V.Rao MD Clostridium difficile by Dr.T.V.Rao MD
Clostridium difficile by Dr.T.V.Rao MD
 
Clostridiumbotulinum
ClostridiumbotulinumClostridiumbotulinum
Clostridiumbotulinum
 
Rotavirus
RotavirusRotavirus
Rotavirus
 
Resistance to anti-microbial agents
Resistance to anti-microbial agentsResistance to anti-microbial agents
Resistance to anti-microbial agents
 
Legionella
Legionella Legionella
Legionella
 
Influenza
InfluenzaInfluenza
Influenza
 
Arboviruses
ArbovirusesArboviruses
Arboviruses
 
Influenza virus
Influenza virus Influenza virus
Influenza virus
 
Vibrio cholera
Vibrio choleraVibrio cholera
Vibrio cholera
 
Adenovirus
AdenovirusAdenovirus
Adenovirus
 
The new β lactamases
The new β lactamasesThe new β lactamases
The new β lactamases
 
Microbiology food poisoning lecture
Microbiology food poisoning lectureMicrobiology food poisoning lecture
Microbiology food poisoning lecture
 

Destaque

C. diff presentation
C. diff presentationC. diff presentation
C. diff presentation
callroom
 
Clostridium difficile infection (cdi)
Clostridium difficile infection (cdi)Clostridium difficile infection (cdi)
Clostridium difficile infection (cdi)
Ren Cartago-Luceno
 
Rifaximin - Fatro worldwide exclusive antibiotic
Rifaximin - Fatro worldwide exclusive antibioticRifaximin - Fatro worldwide exclusive antibiotic
Rifaximin - Fatro worldwide exclusive antibiotic
faroby
 
Periop conference clostridium difficile sep 11 2010
Periop conference   clostridium difficile sep 11 2010Periop conference   clostridium difficile sep 11 2010
Periop conference clostridium difficile sep 11 2010
Maureen Spencer, RN, M.Ed.
 
5 lacerda liver disease
5 lacerda liver disease5 lacerda liver disease
5 lacerda liver disease
angel4567
 
Clostridiumbotulism
ClostridiumbotulismClostridiumbotulism
Clostridiumbotulism
thuytrang246
 
Realizar pruebas para el análisis de infecciones bacterianas y parasitarias
Realizar pruebas para el análisis de infecciones bacterianas y parasitariasRealizar pruebas para el análisis de infecciones bacterianas y parasitarias
Realizar pruebas para el análisis de infecciones bacterianas y parasitarias
UrielPedroza
 

Destaque (18)

C. diff presentation
C. diff presentationC. diff presentation
C. diff presentation
 
Clostridium difficile infection (cdi)
Clostridium difficile infection (cdi)Clostridium difficile infection (cdi)
Clostridium difficile infection (cdi)
 
Clostridium difficile prezentare în limba româna
Clostridium difficile prezentare în limba românaClostridium difficile prezentare în limba româna
Clostridium difficile prezentare în limba româna
 
Rifaximin - Fatro worldwide exclusive antibiotic
Rifaximin - Fatro worldwide exclusive antibioticRifaximin - Fatro worldwide exclusive antibiotic
Rifaximin - Fatro worldwide exclusive antibiotic
 
Periop conference clostridium difficile sep 11 2010
Periop conference   clostridium difficile sep 11 2010Periop conference   clostridium difficile sep 11 2010
Periop conference clostridium difficile sep 11 2010
 
News on surveillance of Clostridium difficile infection (CDI), ECCMID 2016
News on surveillance of Clostridium difficile infection (CDI), ECCMID 2016News on surveillance of Clostridium difficile infection (CDI), ECCMID 2016
News on surveillance of Clostridium difficile infection (CDI), ECCMID 2016
 
Ss16
Ss16Ss16
Ss16
 
Clostridium
ClostridiumClostridium
Clostridium
 
The colossal impact of clostridium difficile infection
The colossal impact of clostridium difficile infection The colossal impact of clostridium difficile infection
The colossal impact of clostridium difficile infection
 
5 lacerda liver disease
5 lacerda liver disease5 lacerda liver disease
5 lacerda liver disease
 
Breakthroughs in the Quest to Cure Cancer
Breakthroughs in the Quest to Cure CancerBreakthroughs in the Quest to Cure Cancer
Breakthroughs in the Quest to Cure Cancer
 
Clostridiumbotulism
ClostridiumbotulismClostridiumbotulism
Clostridiumbotulism
 
Cocina de la sierra PERUANA_PDF
Cocina de la sierra PERUANA_PDFCocina de la sierra PERUANA_PDF
Cocina de la sierra PERUANA_PDF
 
Realizar pruebas para el análisis de infecciones bacterianas y parasitarias
Realizar pruebas para el análisis de infecciones bacterianas y parasitariasRealizar pruebas para el análisis de infecciones bacterianas y parasitarias
Realizar pruebas para el análisis de infecciones bacterianas y parasitarias
 
Rifaximin treatment in hepatic encephalopathy
Rifaximin treatment in hepatic encephalopathyRifaximin treatment in hepatic encephalopathy
Rifaximin treatment in hepatic encephalopathy
 
Cl. botulinum
Cl. botulinumCl. botulinum
Cl. botulinum
 
Clostridium botulinium
Clostridium botuliniumClostridium botulinium
Clostridium botulinium
 
Rifampicin in leprosy
Rifampicin in leprosyRifampicin in leprosy
Rifampicin in leprosy
 

Semelhante a Clostridium difficile 2010

Is Clostridium Difficile still a problem in UK hospitals
Is Clostridium Difficile still a problem in UK hospitalsIs Clostridium Difficile still a problem in UK hospitals
Is Clostridium Difficile still a problem in UK hospitals
Carl Aston
 
Threat of antibiotic resistant bacteria to humans
Threat of antibiotic resistant bacteria to humansThreat of antibiotic resistant bacteria to humans
Threat of antibiotic resistant bacteria to humans
RBKC
 
Antibiotic associated diarrhea
Antibiotic associated diarrheaAntibiotic associated diarrhea
Antibiotic associated diarrhea
Samir Haffar
 
tuberculosis-150808111627-lva1-app6891.pdf
tuberculosis-150808111627-lva1-app6891.pdftuberculosis-150808111627-lva1-app6891.pdf
tuberculosis-150808111627-lva1-app6891.pdf
Shubham Shukla
 
tuberculosis ram. nepal civil service hosp
tuberculosis ram. nepal civil service hosptuberculosis ram. nepal civil service hosp
tuberculosis ram. nepal civil service hosp
RAMJIBANYADAV2
 
THE PREVALENCE OF CLOSTRIDIUM DIFFCILE AT AIREDALE NHST ENVIRONMENT
THE PREVALENCE OF CLOSTRIDIUM DIFFCILE AT AIREDALE NHST ENVIRONMENTTHE PREVALENCE OF CLOSTRIDIUM DIFFCILE AT AIREDALE NHST ENVIRONMENT
THE PREVALENCE OF CLOSTRIDIUM DIFFCILE AT AIREDALE NHST ENVIRONMENT
Willard Dzinyemba
 
Review of Clostridium Difficile
Review of Clostridium DifficileReview of Clostridium Difficile
Review of Clostridium Difficile
Maria Kometer
 
Garey-Austin-ELC-Presentation-022416.pptx
Garey-Austin-ELC-Presentation-022416.pptxGarey-Austin-ELC-Presentation-022416.pptx
Garey-Austin-ELC-Presentation-022416.pptx
Sahil922200
 
Adv. microbiology case study
Adv. microbiology case studyAdv. microbiology case study
Adv. microbiology case study
John Demeter
 

Semelhante a Clostridium difficile 2010 (20)

E045029034
E045029034E045029034
E045029034
 
Is Clostridium Difficile still a problem in UK hospitals
Is Clostridium Difficile still a problem in UK hospitalsIs Clostridium Difficile still a problem in UK hospitals
Is Clostridium Difficile still a problem in UK hospitals
 
Candiduria: current scenario
Candiduria: current scenarioCandiduria: current scenario
Candiduria: current scenario
 
CLOSTRidium defficile lecture DR MOKHTAR.pptx
CLOSTRidium defficile lecture DR MOKHTAR.pptxCLOSTRidium defficile lecture DR MOKHTAR.pptx
CLOSTRidium defficile lecture DR MOKHTAR.pptx
 
Threat of antibiotic resistant bacteria to humans
Threat of antibiotic resistant bacteria to humansThreat of antibiotic resistant bacteria to humans
Threat of antibiotic resistant bacteria to humans
 
Community acquired pneumonia
Community acquired pneumoniaCommunity acquired pneumonia
Community acquired pneumonia
 
Clostridium difficle An emerging Infection
Clostridium difficle An emerging Infection Clostridium difficle An emerging Infection
Clostridium difficle An emerging Infection
 
Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM
Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM
Candida in icu and diagnosis DR M.L. PRASHANTH MD IDCCM
 
Overview of C difficile Infections - Dr Steve Brecher - November 2010 Symposium
Overview of C difficile Infections - Dr Steve Brecher - November 2010 SymposiumOverview of C difficile Infections - Dr Steve Brecher - November 2010 Symposium
Overview of C difficile Infections - Dr Steve Brecher - November 2010 Symposium
 
Tuberculosis - World TB Day 2011
Tuberculosis - World TB Day 2011Tuberculosis - World TB Day 2011
Tuberculosis - World TB Day 2011
 
Antibiotic associated diarrhea
Antibiotic associated diarrheaAntibiotic associated diarrhea
Antibiotic associated diarrhea
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
tuberculosis-150808111627-lva1-app6891.pdf
tuberculosis-150808111627-lva1-app6891.pdftuberculosis-150808111627-lva1-app6891.pdf
tuberculosis-150808111627-lva1-app6891.pdf
 
tuberculosis ram. nepal civil service hosp
tuberculosis ram. nepal civil service hosptuberculosis ram. nepal civil service hosp
tuberculosis ram. nepal civil service hosp
 
THE PREVALENCE OF CLOSTRIDIUM DIFFCILE AT AIREDALE NHST ENVIRONMENT
THE PREVALENCE OF CLOSTRIDIUM DIFFCILE AT AIREDALE NHST ENVIRONMENTTHE PREVALENCE OF CLOSTRIDIUM DIFFCILE AT AIREDALE NHST ENVIRONMENT
THE PREVALENCE OF CLOSTRIDIUM DIFFCILE AT AIREDALE NHST ENVIRONMENT
 
Review of Clostridium Difficile
Review of Clostridium DifficileReview of Clostridium Difficile
Review of Clostridium Difficile
 
Safety measures and infection control
Safety measures and infection controlSafety measures and infection control
Safety measures and infection control
 
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne Infections
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne InfectionsDr. Robert Tauxe - Public Health Concerns About Resistant Foodborne Infections
Dr. Robert Tauxe - Public Health Concerns About Resistant Foodborne Infections
 
Garey-Austin-ELC-Presentation-022416.pptx
Garey-Austin-ELC-Presentation-022416.pptxGarey-Austin-ELC-Presentation-022416.pptx
Garey-Austin-ELC-Presentation-022416.pptx
 
Adv. microbiology case study
Adv. microbiology case studyAdv. microbiology case study
Adv. microbiology case study
 

Mais de Maureen Spencer, RN, M.Ed.

Periop conference working toward zero ssi - sep 11 2010
Periop conference   working toward zero ssi - sep 11 2010Periop conference   working toward zero ssi - sep 11 2010
Periop conference working toward zero ssi - sep 11 2010
Maureen Spencer, RN, M.Ed.
 
Infection control and energy medicine 092108 new york city
Infection control and energy medicine 092108    new york cityInfection control and energy medicine 092108    new york city
Infection control and energy medicine 092108 new york city
Maureen Spencer, RN, M.Ed.
 
Creative hand hygiene programs to motivate staff oct 19 2010
Creative hand hygiene programs to motivate staff oct 19 2010Creative hand hygiene programs to motivate staff oct 19 2010
Creative hand hygiene programs to motivate staff oct 19 2010
Maureen Spencer, RN, M.Ed.
 

Mais de Maureen Spencer, RN, M.Ed. (18)

Establishing a culture of safety april 2012
Establishing a culture of safety   april 2012Establishing a culture of safety   april 2012
Establishing a culture of safety april 2012
 
Periop conference working toward zero ssi - sep 11 2010
Periop conference   working toward zero ssi - sep 11 2010Periop conference   working toward zero ssi - sep 11 2010
Periop conference working toward zero ssi - sep 11 2010
 
Periop conference mrsa and mssa - sep 11 2010
Periop conference   mrsa and mssa - sep 11 2010Periop conference   mrsa and mssa - sep 11 2010
Periop conference mrsa and mssa - sep 11 2010
 
Orthopedic residents orientation july 2010
Orthopedic residents orientation july 2010Orthopedic residents orientation july 2010
Orthopedic residents orientation july 2010
 
Mrsa eradication presentation sep 30 2010
Mrsa eradication presentation sep 30 2010Mrsa eradication presentation sep 30 2010
Mrsa eradication presentation sep 30 2010
 
Mrsa and mssa mna nov 12 2010
Mrsa and mssa   mna nov 12 2010Mrsa and mssa   mna nov 12 2010
Mrsa and mssa mna nov 12 2010
 
Infection control and energy medicine 092108 new york city
Infection control and energy medicine 092108    new york cityInfection control and energy medicine 092108    new york city
Infection control and energy medicine 092108 new york city
 
Evidence based hygiene strategies 102308
Evidence based hygiene strategies 102308Evidence based hygiene strategies 102308
Evidence based hygiene strategies 102308
 
Creative hand hygiene programs to motivate staff oct 19 2010
Creative hand hygiene programs to motivate staff oct 19 2010Creative hand hygiene programs to motivate staff oct 19 2010
Creative hand hygiene programs to motivate staff oct 19 2010
 
Toronto ethicon lecture jan 2010
Toronto ethicon lecture   jan 2010Toronto ethicon lecture   jan 2010
Toronto ethicon lecture jan 2010
 
Mha using measurement to inform and improve
Mha using measurement to inform and improveMha using measurement to inform and improve
Mha using measurement to inform and improve
 
New precaution manual new version june 2010
New precaution manual   new version june 2010New precaution manual   new version june 2010
New precaution manual new version june 2010
 
Yoga in america free download book
Yoga in america free download bookYoga in america free download book
Yoga in america free download book
 
Chakra system slide presentation
Chakra system  slide presentationChakra system  slide presentation
Chakra system slide presentation
 
Yoga and meditation lecture
Yoga and meditation lectureYoga and meditation lecture
Yoga and meditation lecture
 
Anatomy and physiology1
Anatomy and physiology1Anatomy and physiology1
Anatomy and physiology1
 
Ayurveda and asana
Ayurveda and asanaAyurveda and asana
Ayurveda and asana
 
Yoga for diabetes and obesity 2010
Yoga for diabetes and obesity 2010Yoga for diabetes and obesity 2010
Yoga for diabetes and obesity 2010
 

Clostridium difficile 2010

  • 1. Clostridium difficile Infection (CDI) What is it? Modes of transmission? Environmental Sources? Control Measures?
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. States with BI/NAP1/027 strain of C. difficile (N=40), October, 2008 DC PR AK HI
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12. Stomach Acid-Suppressing Medications and Community-Acquired CDAD, England From Dial S, et al. JAMA. 2005;294:2989-2995 .
  • 13. Severe CDAD in Populations Previously at Low Risk—Four States, 2005 CDC. MMWR. 2005;54:1201-1205 . 13 (39) 5 (50) 8 (35) Relapse 5 (15) 2 (20) 3 (13) ER visit necessary 10 (24) 4 (40) 6 (26) Hospitalization necessary 8 (24) 2 (20) 6 (26) Bloody diarrhea 24 (73) 9 (90) 15 (65) Antimicrobial exposure 25 (76) 10 (100) 15 (65) Female 11 (33) 0 (0) 11 (48) Aged < 18 years Total (N=33) Peripartum (N=10) Community (N=23) Characteristic, No. (%)
  • 14.
  • 15.
  • 16.
  • 18. NEBH Cases Per New Definitions
  • 19.
  • 20.
  • 21. 20 4 3 3 10 Total 0 0 0 0 0 Sep 0 0 0 0 0 Aug 1 0 0 0 1 July 2 0 0 1 1 June 2 1 0 0 1 May 3 2 0 0 1 April 2 0 1 1 0 March 2 0 0 0 2 February 1 0 0 0 1 January 5 1 1 1 2 December 0 0 0 0   November 2 0 1 0 1 October Total Community-acquired Indeterminate Community Onset – HAI Hosp Onset Month
  • 22. 0.0 0.11 Rate/PtDays 0.28 Rate/PtDays 0 3 Comm Onset HA 8 Comm Onset HA         0.14 0.35 Rate/PtDays 0.45 Rate/PtDays 1 10 Hospital Onset 13 Hospital Onset         0.14 0.46 Rate/PtDays 0.73 Rate/PtDays 6911 28382 Patient Days 28914 Patient Days 1 13 Total HAI 21 Total HAI FY10 1 st Qtr FY09 FY08
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31. How can C. difficile spores be spread?
  • 32.
  • 33.
  • 34.
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.
  • 51.
  • 52.
  • 53.